EntryPoint Capital LLC Buys 19,862 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

EntryPoint Capital LLC lifted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 214.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,144 shares of the company's stock after purchasing an additional 19,862 shares during the quarter. Castle Biosciences accounts for 0.3% of EntryPoint Capital LLC's holdings, making the stock its 14th largest position. EntryPoint Capital LLC owned 0.10% of Castle Biosciences worth $777,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Perkins Capital Management Inc. raised its holdings in Castle Biosciences by 4.7% in the 4th quarter. Perkins Capital Management Inc. now owns 34,165 shares of the company's stock valued at $910,000 after acquiring an additional 1,525 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Castle Biosciences by 4.8% in the fourth quarter. Vanguard Group Inc. now owns 1,832,535 shares of the company's stock worth $48,837,000 after purchasing an additional 83,783 shares during the period. Fox Run Management L.L.C. acquired a new position in Castle Biosciences in the fourth quarter valued at about $286,000. KLP Kapitalforvaltning AS acquired a new stake in Castle Biosciences during the fourth quarter worth about $128,000. Finally, Sei Investments Co. raised its position in shares of Castle Biosciences by 9.6% in the 4th quarter. Sei Investments Co. now owns 41,491 shares of the company's stock valued at $1,106,000 after buying an additional 3,617 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CSTL. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the stock a "buy" rating in a research report on Friday. Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a report on Thursday, January 2nd. Finally, Robert W. Baird boosted their price target on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $38.75.

Castle Biosciences Price Performance

Shares of NASDAQ:CSTL traded down $0.16 during trading on Friday, hitting $19.94. 203,414 shares of the company were exchanged, compared to its average volume of 369,823. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The company has a market capitalization of $558.46 million, a P/E ratio of 99.70 and a beta of 0.98. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The business's 50 day moving average is $24.19 and its 200-day moving average is $28.00.

Insider Buying and Selling

In related news, Director Daniel Bradbury sold 7,867 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total value of $221,613.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Derek J. Maetzold sold 986 shares of the business's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.03, for a total transaction of $27,637.58. Following the sale, the insider now directly owns 80,818 shares in the company, valued at $2,265,328.54. The trade was a 1.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 45,440 shares of company stock worth $1,081,079 in the last 90 days. Insiders own 7.20% of the company's stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.